Summary & Overview
HCPCS Level II J1553: Immune Globulin (yimmugo) Injection, 100 mg
HCPCS Level II code J1553 denotes a 100 mg injection of immune globulin branded as yimmugo. This code identifies a specific biologic therapy used for immune support or replacement and is relevant for infusion and specialty drug billing nationwide. Accurate coding of J1553 matters for clinical documentation, pharmacy and infusion reimbursement, and supply chain tracking for biologic immunoglobulin products.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides national benchmarks and coding context relevant to these payers, summarizes clinical indications tied to immune globulin therapy, and highlights how this HCPCS Level II drug code fits into billing workflows for infusion centers, hospital outpatient departments, and physician offices.
Readers will learn the code definition and typical sites of service, payer coverage considerations, common claim line practices, and related billing topics. Where input data is missing, the report notes that specific fields are unavailable. The focus is operational clarity for revenue cycle, clinical administrators, and policy analysts handling biologic immunoglobulin administration coded with J1553.
Billing Code Overview
HCPCS Level II code J1553 describes an injection of immune globulin (yimmugo) in a dosage unit of 100 mg. The service type for this code is intravenous or subcutaneous immune globulin administration, used to provide pooled immunoglobulin for immune support or replacement therapy. The typical site of service for administration is infusion center, hospital outpatient department, or physician office depending on clinical setting and patient needs.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with primary immunodeficiency or a patient requiring replacement immune globulin therapy for hypogammaglobulinemia. The patient presents to an infusion suite or outpatient clinic for intravenous or subcutaneous immune globulin administration. The ordering physician documents the indication, weight-based dose, and frequency; pharmacy dispenses J1553 (Injection, immune globulin (yimmugo), 100 mg) in the appropriate number of vials; nursing verifies allergies, vital signs, and informed consent; vascular access is obtained (peripheral IV or subcutaneous infusion set); the product is administered per protocol with monitoring for infusion-related reactions; post-infusion assessment and documentation are completed and the claim is prepared with the appropriate HCPCS code(s) and any applicable modifiers for payer adjudication.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
59 | Distinct procedural service | Use when a separate, distinct service is performed on the same day as another service and documentation supports distinct procedural work unrelated to the infusion. |
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of a procedure |